United States securities and exchange commission logo

                          August 31, 2023

       R. Michael Dudley
       Chief Executive Officer
       Transcode Therapeutics, Inc.
       6 Liberty Square, #2382
       Boston, MA 02109

                                                        Re: Transcode
Therapeutics, Inc.
Statement on Form S-1
                                                            Filed August 29,
                                                            File No. 333-274251

       Dear R. Michael Dudley:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tim
Buchmiller at (202) 551-3635 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Michael Bison, Esq.